呼吸器疾患 診断治療アプローチ 3 肺癌

出版社: 中山書店
著者:
発行日: 2018-02-20
分野: 臨床医学:内科  >  呼吸器一般
ISBN: 9784521745275
電子書籍版: 2018-02-20 (初版第1刷)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:8~14営業日

12,100 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

12,100 円(税込)

商品紹介

近年の肺癌の診断・治療については,driver mutationの発見とそれをターゲットとした薬物の開発による個別化医療が注目され,めざましい進歩を遂げている。本書では薬物治療・内視鏡治療・放射線療法・手術療法・支持療法・先進医療のみならず緩和ケアや予防について,さらには治療の費用対効果についても言及.肺癌診療における最新情報を各分野の専門家がわかりやすく解説している。

目次

  • 1章 肺癌の全体像と現況
    2章 原発性肺癌の診断
    3章 原発性肺癌の治療指針
    4章 原発性肺癌治療の実際
    5章 緩和ケアとインフォームドコンセント
    6章 肺癌の予防対策
    7章 肺癌治療の費用対効果

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1章 肺癌の全体像と現況

P.4 掲載の参考文献
1) 国立がん研究センターがん情報サービス, がん登録・統計. がんに関する統計データのダウンロード. 地域がん登録全国推計によるがん罹患データ (1975年-2013年). http://ganjoho.jp/reg_stat/statistics/dl/index.html. (Accessed 2017年11月24日)
3) 国立がん研究センターがん情報サービス, がん登録・統計. がんに関する統計データのダウンロード. 人口動態統計によるがん死亡データ (1958年-2016年). http://ganjoho.jp/reg_stat/statistics/dl/index.html. (Accessed 2017年11月24日)
4) 厚生労働省. 平成28年国民健康・栄養調査. http://www.mhlw.go.jp/file/04-Houdouhappyou-10904750-Kenkoukyoku-Gantaisakukenkouzoushinka/kekkagaiyou_7.pdf. (Accessed 2017年11月24日)
6) US Department of Health and Human Services. The Health Consequences of Smoking : 50 Years of Progress : a Report of the Surgeon General. 2014. Atlanta, US.
P.11 掲載の参考文献
1) Travis WD, et al. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart, 4th ed. IARC Press ; 2015.
2) Noguchi M, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 1995 ; 75 : 2844-52.
3) Yoshizawa A, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma : prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 2011 ; 24 : 653-64.
4) Miyoshi T, et al. Early-stage lung adenocarcinomas with a micropapillary pattern, a distinct pathologic marker for a significantly poor prognosis. Am J Surg Pathol 2003 ; 27 : 101-9.
5) Inamura K, et al. Pulmonary adenocarcinomas with enteric differentiation : histologic and immunohistochemical characteristics compared with metastatic colorectal cancers and usual pulmonary adenocarcinomas. Am J Surg Pathol 2005 ; 29 : 660-5.
6) Bishop JA, et al. p40 (DeltaNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol 2012 ; 25 : 405-15.
P.17 掲載の参考文献
P.24 掲載の参考文献
1) World Cancer Research Fund/American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer : a Global Perspective. AICR ; 2007.
4) Hirayama T. Non-smoking wives of heavy smokers have a higher risk of lung cancer : a study from Japan. Br Med J (Clin Res Ed) 1981 ; 282 : 183-5.
5) Taylor R, et al. Meta-analysis of studies of passive smoking and lung cancer : effects of study type and continent. Int J Epidemiol 2007 ; 36 : 1048-59.
7) Loomis D, et al. The carcinogenicity of outdoor air pollution. Lancet Oncol 2013 ; 14 : 1262-3.
9) Katanoda K, et al. An association between long-term exposure to ambient air pollution and mortality from lung cancer and respiratory diseases in Japan. J Epidemiol 2011 ; 21 : 132-43.
10) Darby S, et al. Radon in homes and risk of lung cancer : collaborative analysis of individual data from 13 European case-control studies. BMJ 2005 ; 330 : 223.
11) Ye W, et al. Mortality and cancer incidence in Misasa, Japan, a spa area with elevated radon levels. Jpn J Cancer Res 1998 ; 89 : 789-96.
12) Sobue T, et al. Residential randon exposure and lung cancer risk in Misasa, Japan : a case-control study. J Radiat Res 2000 ; 41 : 81-92.
14) Chen CL, et al. Ingested arsenic, cigarette smoking, and lung cancer risk : a follow-up study in arseniasis-endemic areas in Taiwan. JAMA 2004 ; 292 : 2984-90.
16) International Agency for Research on Cancer. Carcinogenicity. In : IARC Handbook of Cancer Prevention. Volume 2 : Carotenoids. IARC ; 1998. p.259-63.

2章 原発性肺癌の診断

P.39 掲載の参考文献
14) Kundel HL, Revesz G. The influence of film density on the radiologic detection of lung lesions. Invest Radiol 1977 ; 12 : 199-200.
16) Krupinski EA, et al. A perceptually based method for enhancing pulmonary nodule recognition. Invest Radiol 1993 ; 28 : 289-94.
18) Manning DJ, et al. Detection or decision errors? Missed lung cancer from the posteroanterior chest radiograph. Br J Radiol 2004 ; 77 : 231-43.
20) Revert A, et al. Measurement of the posterior wall of the intermediate bronchus. Diagnostic value. J Radiol 1990 ; 71 : 97-101.
P.54 掲載の参考文献
1) 日本肺癌学会編集. 臨床・病理 肺癌取扱い規約. 第8版. 金原出版 ; 2017.
2) Shiau MC, et al. Management of solitary pulmonary nodules. In : Clinically Oriented Pulmonary Imaging. Kanne JP, ed. Springer ; 2012, p.19-27.
8) Morimoto K, et al. A pitfall of CT findings in peripheral lung adenocarcinoma. J Comput Assist Tomogr 2002 ; 26 : 197-8.
12) Chaudhuri MR. Primary pulmonary cavitating carcinomas. Thorax 1973 ; 28 : 354-66.
15) Penkrot RJ, Gordon R. Chest xerotomography : evaluation of calcification within lung nodules. Invest Radiol 1980 ; 15 : 517-9.
19) Cymbalista M, et al. CT demonstration of the 1996 AJCC-UICC regional lymph node classification for lung cancer staging. Radiographics 1999 ; 19 : 899-900.
20) 日本CT検診学会肺がん診断基準部会編. 低線量CTによる肺がん検診の肺結節の判定基準と経過観察の考え方. 第4版 (2016年11月改訂). 日本CT検診学会 ; 2016. http://www.jscts.org/pdf/guideline/gls4th201611.pdf
P.60 掲載の参考文献
1) Kubota K. From tumor biology to clinical Pet : a review of positron emission tomography (PET) in oncology. Ann Nucl Med 2001 ; 15 : 471-86.
2) Higashi K, et al. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med 1998 ; 39 : 1016-20.
4) 日本肺癌学会編. EBMの手法による肺癌診療ガイドライン 2016年版, 金原出版 ; 2016.
5) 日本医学放射線学会編. 画像診断ガイドライン 2016年版. 金原出版 ; 2016.
6) NCCN Guidelines Version 9. 2017. Non-Small Cell Lung Cancer. National Comprehensive Cancer Network. http://www.nccn.org/
8) Bury T, et al. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 1998 ; 25 : 1244-7.
14) Lainez S, et al. EBUS-TBNA Can Distinguish Sarcoid-Like Side Effect of Nivolumab Treatment from Tumor Progression in Non-Small Cell Lung Cancer. Respiration 2017 Sep 15. [Epub ahead of print].
17) Toba H, et al. 18F-fluoredeoxyglucose positron emission tomography/computed tomography is useful in postoperative follow-up of asymptomatic non-small-cell lung cancer patients. Interact Cardiovasc Thorac Surg 2012 ; 15 : 859-64.
18) Roberts KB, et al. PET imaging for suspected residual tumour or thoracic recurrence of non-small cell lung cancer after pneumonectomy. Lung Cancer 2005 ; 47 : 49-57.
P.64 掲載の参考文献
2) Das SK, et al. Non-Gaussian diffusion imaging for malignant and benign pulmonary nodule differentiation : a preliminary study. Acta Radiol 2017 ; 58 : 19-26.
11) Kajiwara N, et al. Cine MRI enables better therapeutic planning than CT in cases of possible lung cancer chest wall invasion. Lung Cancer 2010 ; 69 : 203-8.
14) Akeson P, et al. Brain metastases--comparison of gadodiamide injection-enhanced MR imaging at standard and high dose, contrast-enhanced CT and non-contrast-enhanced MR imaging. Acta Radiol 1995 ; 36 : 300-6.
16) Cho H, et al. Pure ground glass nodular adenocarcinomas : Are preoperative positron emission tomography/computed tomography and brain magnetic resonance imaging useful or necessary? J Thorac Cardiovasc Surg 2015 ; 150 : 514-20.
17) Qu X, et al. A meta-analysis of 18 FDG-PET-CT, 18 FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer. Eur J Radiol 2012 ; 81 : 1007-15.
P.69 掲載の参考文献
1) Lindeman NI, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors : guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013 ; 8 : 823-59.
2) 日本肺癌学会バイオマーカー委員会. 肺癌患者におけるEGFR遺伝子変異検査の手引き. 第3.05版. 日本肺癌学会 ; 2016. http://www.haigan.gr.jp/uploads/photos/810.pdf.
3) 日本肺癌学会バイオマーカー委員会. 肺癌患者におけるALK融合遺伝子検査の手引き. 第2版. 日本肺癌学会 ; 2015. http://www.haigan.gr.jp/uploads/photos/1039.pdf.
5) 日本肺癌学会編. 臨床・病理 肺癌取扱い規約. 第8版. 金原出版 ; 2017. p.26-48.
P.76 掲載の参考文献
6) Travis WD, et al. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart, 4th ed. IARC ; 2015.
8) Sasaki E, et al. Breast-specific expression of MGB1/mammaglobin : an examination of 480 tumors from various organs and clinicopathological analysis of MGB1-positive breast cancers. Mod Patholo 2007 ; 20 : 208-14.
9) Ordonez NG. Value of PAX8 immunostaining in tumor diagnosis : a review and updata. Adv Anat Pathol 2012 ; 19 : 140-51.
P.81 掲載の参考文献
1) 日本肺癌学会バイオマーカー委員会編. 肺癌患者におけるEGFR 遺伝子変異検査の手引き 3.05版. 日本肺癌学会 ; 2015. https://www.haigan.gr.jp/uploads/photos/1329.pdf
2) 日本肺癌学会編. EBMの手法による肺癌診療ガイドライン 2016年, 第4版. 金原出版 ; 2016.
3) 日本バイオマーカー委員会編. 肺癌患者におけるALK融合遺伝子検査の手引き, 第2版. 日本肺癌学会 ; 2015. https://www.haigan.gr.jp/uploads/photos/1039.pdf
P.87 掲載の参考文献
2) Stroun M, et al. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta 2001 ; 313 : 139-42.
3) Jahr S, et al. DNA fragments in the blood plasma of cancer patients : quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001 ; 61 : 1659-65.
5) Sueoka-Aragane N, et al. Correlation between plasma DNA and tumor status in an animal model. PLoS One 2014 ; 9 : e111881.
6) コバス(R) EGFR変異検出キット v2.0 添付文書
9) Nakamura T, et al. A noninvasive system for monitoring resistance to epidermal growth factor receptor tyrosine kinase inhibitors with plasma DNA. J Thorac Oncol 2011 ; 6 : 1639-48.
10) Novello S, et al. Metastatic non-small-cell lung cancer : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016 ; 27 (suppl 5) : v1-v27.
11) Sueoka-Aragane N, et al. Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study. Cancer Sci 2016 ; 107 : 162-7.
12) Tan DS, et al. The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer : Status in 2016. J Thorac Oncol 2016 ; 11 : 946-63.
P.91 掲載の参考文献
P.94 掲載の参考文献
1) 日本肺癌学会編. 確定診断. EBMの手法による肺癌診療ガイドライン 2016年, 第4版. 金原出版 ; 2016. p.13-7.
2) Rivera MP, et al. Establishing the diagnosis of lung cancer : Diagnosis and management of lung cancer, 3rd ed : American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013 ; 143 : e142S-65S.
4) Du Rand IA, et al. British Thoracic Society guideline for diagnostic flexible bronchoscopy in adults : accredited by NICE. Thorax 2013 ; 68 Suppl 1 : i1-i44.
P.99 掲載の参考文献
P.103 掲載の参考文献
1) 石井芳樹. 局所麻酔下胸腔鏡検査 : 手技の実際. 気管支学 2002 ; 24 : 557-63.
2) 石井芳樹. 局所麻酔下胸腔鏡検査. 別冊医学のあゆみ. 北村諭ら編. 呼吸器疾患-state of arts 2003-2005. 医歯薬出版 ; 2003. p.209-12.
3) Allen MS, et al. Video-assisted thoracoscopic stapled wedge excision for indeterminate pulmonary nodules. J Thorac Cardiovasc Surg 1993 ; 106 : 1048-52.
7) Dines DE, et al. The value of cells in the pleural fluid in the differential diagnosis. Mayo Clin Proc 1975 ; 50 : 571-2.
P.107 掲載の参考文献
P.112 掲載の参考文献
1) 斎藤達也ほか. 末梢肺病変に対する超音波ガイド下吸引針生検法の診断的有用性について. 日胸疾会誌 1988 ; 26 : 970-4.
2) 松本久子ほか. 縦隔及び末梢型肺野小腫瘤影に対するエコーガイド下肺生検の有用性. 日胸疾会誌 1995 ; 33 : 1319-24.
3) Ikezoe J, et al. Percutaneous biopsy of thoracic lesions : values of sonography for needle guidance. AJR Am J Roentgenol 1990 ; 154 : 1181-5.
4) Yuan A, et al. Ultrasound-guided aspiration biopsy of small peripheral pulmonary nodules. Chest 1992 ; 101 : 926-30.
6) Targhetta R, et al. Peripheral pulmonary lesions : ultrasonic features and ultrasonically guided fine needle aspiration biopsy. J Ultrasound Med 1993 ; 12 : 369-74.
7) Obata K, et al. Repeated ultrasonically guided needle biopsy of small subpleural nodules. Chest 1999 ; 116 : 1320-4.
P.116 掲載の参考文献
1) 大倉久直ほか. 腫瘍マーカー臨床マニュアル. 医学書院 ; 1999.
2) 土屋智史ほか. 外来診療に有用な腫瘍マーカーの知識- 各種疾患の腫瘍マーカー : 肺癌. 臨床と研究 2011 ; 88 : 974-80.
4) Suzuki K, et al. Clinical predictors of N2 disease in the setting of a negative computed tomographic scan in patients with lung cancer. J Thorac Cardiovasc Surg 1999 ; 117 : 593-8.
5) Wang CY, et al. Persistently high serum carcinoembryonic antigen levels after surgery indicate poor prognosis in patients with stage I non-small-cell lung cancer. J Surg Res 2010 ; 163 : e45-50.
6) Satoh H, et al. Serum sialyl lewis X-i antigen levels in non-small cell lung cancer : correlation with distant metastasis and survival. Clin Cancer Res 1997 ; 3 : 495-9.
10) Niho S, et al. Significance of serum pro-gastrin-releasing peptide as a predictor of relapse of small cell lung cancer : comparative evaluation with neuron-specific enolase and carcinoembryonic antigen. Lung Cancer 2000 ; 27 : 159-67.
11) Wojcik E, et al. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer. Anticancer Res 2008 ; 28 : 3027-33.
13) 日本肺癌学会編. EBMの手法による肺癌診療ガイドライン 2016年, 第4版. 金原出版 ; 2016.
14) Okada M, et al. Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer : analysis of 1,000 consecutive resections for clinical stage I disease. Ann Thorac Surg 2004 ; 78 : 216-21.
15) 新海哲ほか. 切除不能原発性肺癌患者におけるCarcinoembryonic antigens (CEA) 測定の意義, 特に癌化学療法との関連について. 癌と化学療法 1984 ; 11 : 1056-63.
P.124 掲載の参考文献
1) 厚生労働省医薬食品局審査管理課長通知「コンパニオン診断薬等及び関連する医薬品の承認申請に係る留意事項について」 (薬食審査発0701第10号). 平成25年 (2013年) 7月1日.
2) Serizawa M, et al. Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays : a prospective, single-institute study. Cancer 2014 ; 120 : 1471-81.
3) 日本肺癌学会バイオマーカー委員会. 肺癌患者におけるEGFR遺伝子変異検査の手引き 第3.05版. 日本肺癌学会 ; 2016. https://www.haigan.gr.jp/uploads/photos/1329.pdf
8) 日本肺癌学会バイオマーカー委員会. 肺癌患者における PD-L1検査の手引き 第1.0版. 日本肺癌学会 ; 2017. https://www.haigan.gr.jp/uploads/photos/1400.pdf
11) Qin X, et al. Cisplatin induces programmed death-1-ligand 1 (PD-L1) over-expression in hepatoma H22 cells via Erk/MAPK signaling pathway. Cell Mol Biol (Noisy-le-grand) 2010 ; 56 Suppl : OL1366-72.
12) Zhang P, et al. Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. Mol Immunol 2008 ; 45 : 1470-6.
13) コバスREGFR変異検出キット v2.0 添付文書. 2016年12月改訂 (第3版). http://www.info.pmda.go.jp/downfiles/ivd/PDF/700025_22800EZX00011000_A_01_05.pdf
14) Thress KS, et al. EGFR mutation detection in ctDNA from NSCLC patient plasma : A cross-plat form comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer 2015 ; 90 : 509-15.
15) Ilie M, et al. "Sentinel" circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease. PLoS One 2014 ; 9 : e111597.
17) OncoGuide(R) AmoyDx(R) ROS1融合遺伝子検出キット添付文書.
18) Sugiyama E, et al. Clinical features of squamous cell lung cancer with targetable gene alterations in a nationwide genomic screening network in Japan (LC-SCRUM-Japan). 2017 ; ASCO, 9057.
P.133 掲載の参考文献
1) Brierley JD, et al. eds. TNM Classification of Malignant Tumours, 8th ed. Wiley-Blackwell ; 2017.
2) Rami-Porta R, et al. The IASLC lung cancer staging project : the new database to inform the eighth edition of the TNM classification of lung cancer. J Thorac Oncol 2014 ; 9 : 1618-24.
3) 日本肺癌学会編. 臨床・病理肺癌取扱い規約, 第8版. 金原出版 ; 2016.
4) Wittekind C, et al. eds. TNM Supplement : A Commentary on Uniform Use. 3rd ed. Wiley ; 2003.
5) Travis WD, et al. The IASLC Lung Cancer Staging Project : Proposals for coding T categories for subsolid nodules and assessment of tumor size in part-solid tumors in the forthcoming eighth edition of the TNM classification of lung cancer. J Thorac Oncol 2016 ; 11 : 1204-23.

3章 原発性肺癌の治療方針

P.141 掲載の参考文献
1) Chang JY, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer : a pooled analysis of two randomised trials. Lancet Oncol 2015 ; 16 : 630-7.
3) Pignon JP, et al. Lung adjuvant cisplatin evaluation : a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008 ; 26 : 3552-9.
4) Goto K, et al. Phase II study of crizotinib in east Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 2016 ; 34 (15_suppl) : 9022.
7) Mok TS, et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med 2017 ; 376 : 629-40.
9) Yoshida K, et al. Overall Survival (OS) of EGFR Mutation Positive Non-Small Cell Lung Cancer Patients : Real-World Treatment Patterns of 1,660 Japanese Patients. J Thorac Oncol 2017 : 12 : S336-7.
10) Brahmer J, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015 ; 373 : 123-35.
13) Garon EB, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL) : a multicentre, double-blind, randomised phase 3 trial. Lancet 2014 ; 384 : 665-73.
14) Nishio M, et al. EAST-LC : Randomized controlled phase III trial of S-1 versus docetaxel in patients with non-small-cell lung cancer who had received a platinum-based treatment. Annals of Oncol 2016 ; 27 (Suppl 6) ; 1218PD.
15) Wu YL, et al. Gefitinib (G) versus vinorelbine+cisplatin (VP) as adjuvant treatment in stage II-IIIA (N1-N2) non-small-cell lung cancer (NSCLC) with EGFR-activating mutation (ADJUVANT) : A randomized, Phase III trial (CTONG 1104). J Clin Oncol 2017 ; 35 (15_suppl. 8500).
16) Chaft JE, et al. Neoadjuvant nivolumab in early-stage, resectable non-small cell lung cancers. J Clin Oncol 2017 : 35 (suppl ; abstr 8508)
P.147 掲載の参考文献
1) 日本肺癌学会編. EBMの手法による肺癌診療ガイドライン. 金原出版 ; 2016.
2) Hida T, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX) : an open-label, randomised phase 3 trial. Lancet 2017 ; 390 : 29-39.
5) O'Brien ME, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006 ; 24 : 5441-7.
P.154 掲載の参考文献
4) Yu HA, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013 ; 19 : 2240-7.
5) Mok TS, et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med 2017 ; 376 : 629-40.
12) Shaw AT, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 2014 ; 371 : 1963-71.
20) Sandler A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006 ; 355 : 2542-50.
21) Garon EB, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL) : a multicentre, double-blind, randomised phase 3 trial. Lancet 2014 ; 384 : 665-73.
P.162 掲載の参考文献
1) 日本肺癌学会編. EBMの手法による肺癌診療ガイドライン 2016年版. 金原出版 ; 2016.
3) Pignon JP, et al. Lung adjuvant cisplatin evaluation : a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008 ; 26 : 3552-9.
4) NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer : a systematic review and meta-analysis of individual participant data. Lancet 2014 ; 383 : 1561-71.
7) Bradley JD, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617) : a randomised, two-by-two factorial phase 3 study. Lancet Oncol 2015 ; 16 : 187-99.
9) Albain KS, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer : a phase III randomised controlled trial. Lancet 2009 ; 374 : 379-86.
12) Watanabe Y, et al. Mediastinal nodal involvement and the prognosis of non-small cell lung cancer. Chest 1991 ; 100 : 422-8.
P.168 掲載の参考文献
1) Sacher AG, et al. Elderly patients with advanced NSCLC in phase III clinical trials : are the elderly excluded from practice-changing trials in advanced NSCLC? J Thorac Oncol 2013 ; 8 : 366-8.
2) 林直美, 安藤雄一. 超高齢がん患者, なにをどこまでやるべきか-臨床での意思決定を支える評価法とスクリーニングツール. Cancer Board Square 2016 ; 2 : 260-6.
3) McGarry RC, et al. Observation-only management of early stage, medically inoperable lung cancer : poor outcome. Chest 2002 ; 121 : 1155-8.
4) Eguchi T, et al. Impact of Increasing Age on Cause-Specific Mortality and Morbidity in Patients With Stage I Non-Small-Cell Lung Cancer : A Competing Risks Analysis. J Clin Oncol 2017 ; 35 : 281-90.
5) Atagi S, et al. Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer : a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol 2012 ; 13 : 671-8.
6) Aoe K, et al. A phase II study of S-1 chemotherapy with concurrent thoracic radiotherapy in elderly patients with locally advanced non-small-cell lung cancer : the Okayama Lung Cancer Study Group Trial 0801. Eur J Cancer 2014 ; 50 : 2783-90.
7) Maemondo M, et al. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations : NEJ 003 study. J Thorac Oncol 2012 ; 7 : 1417-22.
9) Kuyama S, et al. A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor : The Okayama Lung Cancer Study Group Trial 1202. Lung Cancer 2017 ; 112 : 188-94.
10) Kubo T, et al. A phase II study of topotecan and cisplatin with sequential thoracic radiotherapy in elderly patients with small-cell lung cancer : Okayama Lung Cancer Study Group 0102. Cancer Chemother Pharmacol 2016 ; 78 : 769-74.
P.172 掲載の参考文献
1) 厚生労働省科学研究費補助金難治性疾患政策研究事業「びまん性肺疾患に関する調査研究」班特発性肺線維症の治療ガイドライン作成委員会編. 特発性肺線維症の治療ガイドライン 2017. 南江堂 ; 2017.
2) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会編. 特発性間質性肺炎 診断と治療の手引き, 改訂第3版. 南江堂 ; 2016.
3) Ley B, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012 ; 156 : 684-91.
5) Sato T, et al. A simple risk scoring system for predicting acute exacerbation of interstitial pneumonia after pulmonary resection in lung cancer patients. Gen Thorac Cardiovasc Surg 2015 ; 63 : 164-72.
10) Minegishi Y, et al. The feasibility study of carboplatin plus etoposide for advanced small cell lung cancer with idiopathic interstitial pneumonias. J Thoracic Oncol 2011 ; 6 : 801-7.
11) 弦間昭彦, 峯岸裕司. 特発性間質性肺炎合併肺癌に対する化学療法の現況と治療関連急性増悪に関する実態調査. びまん性肺疾患に関する調査研究班. 平成21年度研究報告書. 2010. p.105-7.
12) 峯岸裕司ほか. 特発性間質性肺炎合併進行/術後再発肺癌の二次治療以降の化学療法に関する実態調査. びまん性肺疾患に関する調査研究班. 平成24年度研究報告書. 2013. p.164-9.
P.181 掲載の参考文献
1) PDQ Supportive and Palliative Care Editorial Board. Cardiopulmonary Syndromes (PDQ(R)) -Health Professional Version, National Cancer Institute Published Online, 2016.
5) Loblaw DA, et al Systematic review of the diagnosis and management of malignant extradural spinal cord compression : the Cancer Care Ontario Practice Guidelines Initiative's Neuro-Oncology Disease Site Group. J Clin Oncol 2005 ; 23 : 2028-37.
6) 津端由佳里. 高カルシウム血症と低ナトリウム血症. 呼吸器内科 2014 ; 25 : 411-8.

4章 原発性肺癌治療の実際

P.189 掲載の参考文献
1) Ginsberg RJ, et al. Randomized trial of lobectomy versus limited resection for T1N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1995 ; 60 : 615-22.
5) El-Sherif A, et al. Outcomes of sublobar resection versus lobectomy for stage I non-small cell lung cancer : a 13-year analysis. Ann Thorac Surg 2006 ; 82 : 408-15.
6) Nakamula H, et al. Survival following lobectomy vs limited resection for stage I lung cancer : a meta-analysis. Br J Cancer 2005 ; 92 : 1033-7.
7) Tsubota N, et al. Ongoing prospective study of segmentectomy for small lung tumors. Study Group of Extended Segmentectomy for Small Lung Tumor. Ann Thorac Surg 1998 ; 66 : 1787-90.
11) Martin-Ucar AE, et al. A case-matched study of anatomical segmentectomy versus lobectomy for stage I lung cancer in high-risk patients. Eur J Cardiothorac Surg 2005 ; 27 : 675-9.
12) Downey RJ, et al. Extent of chest wall invasion and survival in patients with lung cancer. Ann Thorac Surg 1999 ; 68 : 188-93.
P.192 掲載の参考文献
P.200 掲載の参考文献
1) 日本肺癌学会編. EBMの手法による肺癌診療ガイドライン 2016年版. 金原出版 ; 2016.
2) National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
3) National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf
4) 日本放射線腫瘍学会編. 非小細胞肺癌. 放射線治療計画ガイドライン 2016年版. 金原出版 ; 2016. p.143-9,
5) 日本放射線腫瘍学会編. 小細胞肺癌. 放射線治療計画ガイドライン 2016年版. 金原出版 ; 2016. p.150-6.
6) Bradley JD, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617) : a randomised, two-by-two factorial phase 3 study. Lancet Oncol 2015 ; 16 : 187-99.
7) Hata E, et al. Rationale for extended lymphadenectomy for lung cancer. Theor Surg 1990 ; 5 : 19-25.
8) 小宮山貴史ほか. 肺癌放射線治療計画のためのリンパ節部位のCTアトラス. 肺癌 2015 ; 55 : 189-205.
9) Chang JY, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer : a pooled analysis of two randomised trials. Lancet Oncol 2015 ; 16 : 630-7.
P.206 掲載の参考文献
2) Serizawa M, et al. Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays : a prospective, single-institute study. Cancer 2014 ; 120 : 1471-81.
3) Maemondo M, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010 ; 362 : 2380-8.
6) Rosell R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC) : a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012 ; 13 : 239-46.
8) Yang JJ, et al. A randomized controlled trial of erlotinib versus gefitinib in advanced non-small-cell lung cancer harboring EGFR mutations (CTONG0901). J Thorac Oncol 2015 ; 10 (Suppl 2) : S321 (abstr).
10) Wu YL, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6) : an openlabel, randomised phase 3 trial. Lancet Oncol 2014 ; 15 : 213-22.
12) Mok TS, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 2017 ; 376 : 629-40.
14) Nokihara H, et al. Alectinib (ALC) versus crizotinib (CRZ) in AKL-inhibitor naive ALK-positive non-small cell lung cancer (ALK+NSCLC) : primary results from the J-ALEX study. J Clin Oncol 2016 ; 34 (suppl ; abstr 9008).
18) Goto K, et al. Phase II study of crizotinib in east Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2016 ; 34 (suppl ; abstr 9022).
20) Ou SH, et al. Alectinib in crizotinib-refcatory ALK-rearranged non-small-cell lung cancer : a phase II global study. J Clin Oncol 2016 ; 34 : 661-8.
P.214 掲載の参考文献
1) Willox JC, et al. Effects of magnesium supplementation in testicular cancer patients receiving cisplatin : a randomised trial. Br J Cancer 1986 ; 54 : 19-23.
2) Tiseo M, et al. Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatinbased chemotherapy for outpatient treatment in lung cancer and mesothelioma. Tumori 2007 ; 93 : 138-44.
4) Basch E, et al. Antiemetics : American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011 ; 29 : 4189-98.
6) Nishio M, et al. EAST-LC : Randomized controlled phase III trial of S-1 versus docetaxel in patients with non-small-cell lung cancer who had received a platinum-based treatment. Ann Oncol 2016 ; 27 : 1218PD.
7) Minami H, et al. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymor phisms in Japanese : roles of UGT1A1 * 6 and * 28. Pharmacogenet Genomics 2007 ; 17 : 497-504.
P.222 掲載の参考文献
3) Sandler A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006 ; 355 : 2542-50.
6) Zhou C, et al. BEYOND : A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol 2015 ; 33 : 2197-204.
7) アバスチン適正使用検討委員会監. アバスチン, 扁平上皮癌を除く切除不能な進行・再発の非小細胞肺癌に用いる際に, 適正使用ガイド. 中外製薬 ; 2016.
8) Garon EB, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL) : a multicentre, double-blind, randomised phase 3 trial. Lancet 2014 ; 384 : 665-73.
9) Yoh K, et al. A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy. Lung Cancer 2016 ; 99 : 186-93.
10) サイラムザ非小細胞肺癌適正使用アドバイザリーボード. サイラムザ, 切除不能な進行・再発の非小細胞肺癌, 適正使用ガイド. 日本イーライリリー ; 2016.
12) Seto T, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567) : an open-label, randomised, multicentre, phase 2 study. Lancet Oncol 2014 ; 15 : 1236-44.
14) 日本癌治療学会編. G-CSF適正使用ガイドライン 2013年版, Ver.4. http://www.jsco-cpg.jp/item/30/index.html
P.229 掲載の参考文献
6) 厚生労働省. ニボルマブ (遺伝子組換え) 製剤及びペムブロリズマブ (遺伝子組換え) 製剤の最適使用推進ガイドライン (非小細胞肺癌及び悪性黒色腫) について. 薬生薬審発 0214 第1号. 平成29年2月14日.
P.234 掲載の参考文献
P.244 掲載の参考文献
1) 日本肺癌学会編. EBMの手法による肺癌診療ガイドライン 2016年版. 金原出版 ; 2016.
4) Seto T, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567) : an open-label, randomised, multicentre, phase 2 study. Lancet Oncol 2014 ; 15 : 1236-44.
7) Hida T, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX) : an open-label, randomised phase 3 trial. Lancet 2017 ; 390 : 29-39.
10) Goto K, et al. Phase II study of crizotinib in east Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSLC). J Clin Oncol 2016 ; 34 (suppl : abstr 9022).
12) Kubota K, et al. A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer : TCOG0701 CATS trial. Ann Oncol 2015 ; 26 : 1401-8.
13) Okamoto I, et al. Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer : results of a west Japan oncology group study. J Clin Oncol 2010 ; 28 : 5240-6.
16) Sandler A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006 ; 355 : 2542-50.
P.247 掲載の参考文献
P.259 掲載の参考文献
3) Garon EB, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL) : a multicentre, double-blind, randomised phase 3 trial. Lancet 2014 ; 384 : 665-73.
4) Yoh K, et al. A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy. Lung Cancer 2016 ; 99 : 186-93.
5) Nishio M, et al. EAST-LC : Randomized controlled phase III trial of S-1 versus docetaxel in patients with non-small-cell lung cancer who had received a platinum-based treatment. Annals of Oncol 2016 ; 27.
6) Mok TS, et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M Positive Lung Cancer. N Engl J Med 2017 ; 376 : 629-40.
8) Soria JC, et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutationpositive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS) : a phase 3 randomised trial. Lancet Oncol 2015 ; 16 : 990-8.
P.261 掲載の参考文献
2) Soria JC, et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on firstline gefitinib (IMPRESS) : a phase 3 randomised trial. Lancet Oncol 2015 ; 16 : 990-8.
P.266 掲載の参考文献
1) 日本肺癌学会編. EBMの手法による肺癌診療ガイドライン 2016年版. 金原出版 ; 2016.
2) Tsuchiya R, et al. Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer : the Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101). J Thorac Cardiovasc Surg 2005 ; 129 : 977-83.
8) Auperin A, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999 ; 341 : 476-84.
P.272 掲載の参考文献
2) O'Brien ME, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006 ; 24 : 5441-7.
3) Takeda K, et al. A phase II study of topotecan in patients with relapsed small-cell lung cancer. Clin Lung Cancer 2003 ; 4 : 224-8.
7) Murakami H, et al. A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer : Japan Clinical Oncology Group Study (JCOG0901). Lung Cancer 2014 ; 84 : 67-72.
P.276 掲載の参考文献
1) Hayata Y, et al. Hematoporphyrin deriveative and laser photoradiation in the treatment of lung cancer. Chest 1982 ; 81 : 269-77.
2) Kato H, et al. Phase II clinical study of photodynamic therapy using mono-L-aspartyl chlorin e6 and diode laser for early superficiall squamous cell carcinoma of the lung. Lung Cancer 2003 ; 42 : 103-11.
P.280 掲載の参考文献
1) Ost ED, et al. Therapeutic bronchoscopy for malignant central airway obstruction : successs rates and impact on dyspnea and quality of life. Chest 2015 ; 147 : 1282-98.
2) Ernst A, et al. Interventional pulmonary procedures : Guidelines from American College of Chest Physicians. Chest 2003 ; 123 : 1693-717.
3) Dooms C, et al. Performance of fully coverd self-expanding metallic stent in benign airway strictures. Respiration 2009 ; 77 : 420-6.
P.284 掲載の参考文献
浅野文祐, 宮澤輝臣. 気管支鏡ベストテクニック, 改訂2版. 中外医学社 ; 2017, p.198-253.
P.290 掲載の参考文献
2) Hesketh PJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting : a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003 ; 21 : 4112-9.
17) Rosen LS, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors : a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003 ; 21 : 3150-7.
27) Ruggiero SL, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg 2014 ; 72 : 1938-56.
28) 顎骨壊死検討委員会編. 骨吸収抑制薬関連顎骨壊死の病態と管理 : 顎骨壊死検討委員会ポジションペーパー 2016. http://www.perio.jp/file/news/info_160926.pdf
29) Otto S, et al. Tooth extraction in patients receiving oral or intravenous bisphosphonate administration : A trigger for BRONJ development? J Craniomaxillofac Surg 2015 ; 43 : 847-54.
32) Coleman R, et al. Bone health in cancer patients : ESMO Clinical Practice Guidelines. Ann Oncol 2014 ; 25 Suppl 3 : iii124-37.
P.298 掲載の参考文献
1) Particle Therapy Co-Operative Group. Particle therapy facilities in operation (last update : July 2017). https://www.ptcog.ch/index.php/facilities-in-operation
2) 日本放射線治療学会. 粒子線治療の疾患別統一治療方針. https://www.jastro.or.jp/particle_beam/2017/10/post-3.html
3) 日本粒子線治療臨床研究会. 日本国内の粒子線治療施設の治療データ集計結果 (1979年~2014年). http://jcpt.kenkyuukai.jp/special/?id=805
4) Makita C, et al. High-dose proton beam therapy for stage I non-small cell lung cancer : Clinical outcomes and prognostic factors. Acta Oncol 2015 ; 54 : 307-14.
5) Kanemoto A, et al. Outcomes and prognostic factors for recurrence after high-dose proton beam therapy for centrally and peripherally located stage I non-small-cell lung cancer. Clin Lung Cancer 2014 ; 15 : e7-12.
7) Iwata H, et al. Long-term outcome of proton therapy and carbon-ion therapy for large (T2a-T2b-N0M0) non-small-cell lung cancer. J Thorac Oncol 2013 ; 8 : 726-35.
8) Iwata H, et al. High-dose proton therapy and carbon-ion therapy for stage I non-small cell lung cancer. Cancer 2010 ; 116 : 2476-85.
12) Miyamoto T, et al. Carbon ion radiotherapy for stage I non-small cell lung cancer using a regimen of four fractions during 1 week. J Thorac Oncol 2007 ; 2 : 916-26.
13) Takahashi W, et al. A prospective nonrandomized phase I/II study of carbon ion radiotherapy in a favorable subset of locally advanced non-small cell lung cancer (NSCLC). Cancer 2015 ; 121 : 1321-7.

5章 緩和ケアとインフォームドコンセント

P.304 掲載の参考文献
1) 日本緩和医療学会緩和医療ガイドライン委員会編. がん患者の呼吸器症状の緩和に関するガイドライン, 2016年版. 金原出版 ; 2016.
2) 日本緩和医療学会編. 専門家をめざす人のための緩和医療学. 南江堂 ; 2014, p.148-58.
5) 清水哲郎. 本人・家族の意思決定を支える-治療方針選択から将来に向けての心積りまで. 医療と社会 2015 ; 25 : 35-48.
P.309 掲載の参考文献
1) 日本緩和医療学会緩和医療ガイドライン作成委員会編. がん疼痛の薬物療法に関するガイドライン (2014年版). 金原出版 ; 2014. p.18-41, 97-114.
3) 森田達也. 緩和ケアレジデントマニュアル. 西智弘ほか編. 医学書院 ; 2016, p.114-21.
4) 日本ペインクリニック学会治療指針検討委員会編. ペインクリニック治療指針, 改訂第5版. 真興交易医書出版部 ; 2016. p.1-58.
P.316 掲載の参考文献
1) Derogatis LR, et al. The prevalence of psychiatric disorders among cancer patients. JAMA 1983 ; 249 : 751-7.
3) Uchitomi Y, et al. Depression and psychological distress in patients during the year after curative resection of non-small-cell lung cancer. J Clin Oncol 2003 ; 21 : 69-77.
4) American Psychiatric Association. Diagnostic and statistical manual of mental disorders 5th edition (精神疾患の診断・統計マニュアル 第5版), 2013.
6) Shin JY, et al. Risk of intracranial haemorrhage in antidepressant users with concurrent use of nonsteroidal anti-inflammatory drugs : nationwide propensity score matched study. BMJ 2015 ; 351 : h3517.
P.320 掲載の参考文献
1) Plato. The collected dialogues of Plato including the letters. Hamilton E, Cairns H, ed. Princeton, N. J. : Princeton University Press ; 1963. p.720 c-e.
2) 中村雄二郎. 臨床の知とは何か. 岩波新書 ; 1992.
3) 星野一正. インフォームドコンセント. 丸善 ; 1997.
4) 星野一正. 医療の倫理. 岩波新書 ; 1991.
5) 藤山雅行編. 判例にみる医師の説明義務. 新日本法規出版 ; 2006.
6) Enzinger AC, et al. Outcomes of Prognostic Disclosure : Associations With Prognostic Understanding, Distress, and Relationship With Physician Among Patients With Advanced Cancer. J Clin Oncol 2015 ; 33 : 3809-16.
8) Baile WF, et al. SPIKES-A six-step protocol for delivering bad news : application to the patient with cancer. Oncologist 2000 ; 5 : 302-11.

6章 肺癌の予防対策

P.328 掲載の参考文献
2) Sagawa M, et al. The efficacy of lung cancer screening conducted in 1990s : four case-control studies in Japan. Lung Cancer 2003 ; 41 : 29-36.
3) Fontana RS, et al. Screening for lung cancer. A critique of the Mayo Lung Project. Cancer 1991 ; 67 : 1155-64.
6) National Lung Screening Trial Research Team, Aberle DR, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. New Engl J Med 2011 ; 365 : 395-409.
7) Patz EF Jr, et al. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Int Med 2014 ; 174 : 269-74.
P.334 掲載の参考文献
1) Balfour DJ. Neural mechanisms underlying nicotine dependence. Addiction 1994 ; 89 : 1419-23.
2) Fagerstrom KO, Schneider NG. Measuring nicotine dependence : a review of the Fagerstrom Tolerance Questionnaire. J Behav Med 1989 ; 12 : 159-82.
3) Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel. Liaisons, and Staff. A clinical practice guideline treating tobacco use and dependence ; 2008 update. A U.S. Public Health Service report. Am J Prev Med 2008 ; 35 : 158-76.
5) 日本循環器学会, 日本肺癌学会, 日本癌学会, 日本呼吸器学会編. 禁煙治療のための標準手順書, 改訂第6版. 2016.
6) 日本禁煙学会. 若年者の禁煙治療指針. 日本禁煙学会雑誌 2016 ; 11 : 145-51.
7) 中村正和, 大島明. 明日からタバコがやめられる, 禁煙セルフヘルプブック. 法研 ; 1999, p.78-9.
P.338 掲載の参考文献
2) Soria JC, et al. Chemoprevention of lung cancer. Lancet Oncol 2003 ; 4 : 659-69.
9) Hirsch FR, et al. Role of biomarkers for early detection of lung cancer and chemoprevention. Eur Respir J 2002 ; 19 : 1151-8.
11) Meuwissen R, et al. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell 2003 ; 4 : 181-9.
13) Ueno T, et al. Non-invasive X-ray micro-computed tomography evaluation of indomethacin on urethane-induced lung carcinogenesis in mice. Anticancer Res 2012 ; 32 : 4773-80.

7章 肺癌治療の費用対効果

P.345 掲載の参考文献
1) 池田俊也ほか. 日本語版EQ-5D-5Lにおけるスコアリング法の開発. 保健医療科学 2015 ; 64 : 47-55.
4) Reck M, et al. Overall health status (HS) in patients (pts) with advanced (adv) non-squamous (NSQ) NSCLC treated with nivolumab (nivo) or docetaxel (doc) in CheckMate 057. Annals of Oncology 2016 ; 27 (suppl 6) : 1217PD.
6) 大日康史, 菅原民枝. 1QALY獲得に対する最大支払い意思額に関する研究. 医療と社会 2006 ; 16 : 157-65.

最近チェックした商品履歴

Loading...